How ConsumerAffairs uses cookies

This website utilizes technologies such as cookies to enable essential site functionality, as well as for analytics, personalization, and targeted advertising. To learn more, view the following link:

We're there for consumers when it counts — with the right information, right on time.

Donate to our work

Kristen Dalli

Independent journalism since 1998

Kyle James

70,000+ consumer news stories published

Mark Huffman

Your support helps us invest in our mission to empower consumers to make informed decisions.

ConsumerAffairs is a for-profit company. Your contribution is not tax deductible.

FDA approves Roche’s new breast cancer pill

Image (c) ConsumerAffairs - The FDA approves Roche's new pill with everolimus for advanced breast cancer, reducing progression risk by 62% in ESR1 mutation patients.

Wilserdly targets a form of advanced disease that can become resistant to hormone therapy

  • The FDA has approved Roche’s Wilserdly, taken with everolimus, for certain adults with advanced breast cancer that has returned or progressed after hormone treatment.

  • In patients with an ESR1 mutation, the combination reduced the risk of disease progression or death by 62% compared with standard hormone therapy plus everolimus.

  • The treatment is entirely oral, offering an option that does not require injections, although patients still need monitoring for side effects.


The Food and Drug Administration has approved Roche’s breast cancer drug Wilserdly, providing a new treatment option for patients whose disease has become harder to control with hormone therapy.

The approval covers the drug, also known as giredestrant, in combination with everolimus for adults with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with an ESR1 mutation. Eligible patients must have experienced recurrence during or after hormone-based treatment following initial therapy, or progression after hormone treatment for metastatic disease.

ESR1 mutations can allow cancer to resist hormone treatments. According to Roche, these mutations develop in up to 40% of patients with hormone receptor-positive metastatic breast cancer.

Wilserdly belongs to a class called selective estrogen receptor degraders, or SERDs. The combination targets two different signaling pathways involved in cancer growth, Roche said. Both medicines are taken orally, allowing patients to take their treatment at home.

Successful phase 3 clinical trial

The approval was supported by the phase 3 evERA Breast Cancer trial. Among patients with ESR1-mutated tumors, median progression-free survival — the time before cancer worsened or a patient died — was 10 months with the new combination, compared with 5.5 months for standard endocrine therapy plus everolimus.

Overall survival results were not yet mature, so the findings do not establish that the treatment helps patients live longer.

Treatment carries risks. Common side effects included mouth inflammation, rash, fatigue, diarrhea, muscle and joint pain, lung inflammation and nausea. The prescribing information also warns about a slow heartbeat and potential harm to a developing fetus.

Roche is also seeking approval for giredestrant after initial treatment of certain earlier-stage breast cancers, when therapy is intended to reduce the risk of recurrence. The company said an FDA decision on that separate application is expected by November 30.

That pending decision could expand the medicine’s role beyond advanced disease. The current approval applies specifically to the previously treated, ESR1-mutated population.


Stay informed

Sign up for The Daily Consumer

Get the latest on recalls, scams, lawsuits, and more

    By entering your email, you agree to sign up for consumer news, tips and giveaways from ConsumerAffairs. Unsubscribe at any time.

    Thanks for subscribing.

    You have successfully subscribed to our newsletter! Enjoy reading our tips and recommendations.

    Was this article helpful?

    Share your experience about ConsumerAffairs

    Was this article helpful?

    Share your experience about ConsumerAffairs